Öztürk H, Karapolat İ. Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer. World J Clin Cases 2023; 11(36): 8447-8457 [PMID: 38188218 DOI: 10.12998/wjcc.v11.i36.8447]
Corresponding Author of This Article
Hakan Öztürk, MD, Adjunct Associate Professor, Associate Professor, Department of Urology, Izmir University of Economics, 1825 sok no 12 Medicalpoint Hospital, Karsiyaka Izmir 35330, Turkey. drhakanozturk@yahoo.com.tr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 26, 2023; 11(36): 8447-8457 Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8447
Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer
Hakan Öztürk, İnanç Karapolat
Hakan Öztürk, Department of Urology, Izmir University of Economics, Karsiyaka Izmir 35330, Turkey
İnanç Karapolat, Department of Nuclear Medicine, School of Medicine, İzmir Tınaztepe University, Izmir 35000, Turkey
Author contributions: Öztürk H participated in the design of the study and performed the statistical analysis; Karapolat İ carried out the nuclear medicine studies; Öztürk H and Karapolat İ drafted the manuscript; Öztürk H conceived the study, and participated in its design and coordination; all authors read and approved the final manuscript.
Institutional review board statement: There is no need approval. The research method is data analysis.
Informed consent statement: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. Additional information consent was obtained from all patients for which identifying information is included in this article.
Conflict-of-interest statement: All the authors declare that they have no competing interests. Financial support has not been received.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hakan Öztürk, MD, Adjunct Associate Professor, Associate Professor, Department of Urology, Izmir University of Economics, 1825 sok no 12 Medicalpoint Hospital, Karsiyaka Izmir 35330, Turkey. drhakanozturk@yahoo.com.tr
Received: September 22, 2023 Peer-review started: September 22, 2023 First decision: November 9, 2023 Revised: November 10, 2023 Accepted: December 6, 2023 Article in press: December 6, 2023 Published online: December 26, 2023 Processing time: 90 Days and 16.2 Hours
ARTICLE HIGHLIGHTS
Research perspectives
More sensitive scanning methods are needed such as positron emission tomography (PET)/magnetic resonance imaging (MRI), metabolic-based imaging.
Research conclusions
Use PET/computed tomography (CT) more for accurate staging regardless of whether fluorodeoxyglucose (FDG) is excreted from the urinary tract. PET/CT can be standart in muscle-invasive bladder carcinoma
Research results
Restaging with high accuracy can protect patients from secondary or even tertiary chemotheraphy. Of the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent. Imaging techniques that detect every behavior of the tumor will increase the success of future treatment. This study is an example of this. In fact, PET-MRI may become the standard instead of PET/CT in the future. Their contributions to the overall research in this field, and the problems that remain to be solved; There is still only limited data on the benefits of 18Fluorodeoxyglucose positron emission tomography computed tomography (18FDG PET/CT) in the identification of recurrences and new metastases after first-line chemotherapy for metastatic bladder cancer, and evaluating responses to therapy in cancer patients is still just as challenging as before. The reason for this is that; with current imaging techniques it is not possible to detect with absolute accuracy after chemotherapy to what extent of metastatic focus has been affected by the chemotherapeutics.
Research methods
The research method is data analysis.
Research objectives
To contribute to the literature in this field. We believe that, this study will guide in the future. We see that data pool is beeing increased in this field.
Research motivation
Urooncology and Nuclear Medicine departments study as multidisciplinary. Scientific data is discussed in the council and outputs are produced.
Research background
The purpose of the present study was to examine retrospectively the contribution of 18FDG-PET/CT to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer. An accurate primary staging of the disease is particularly important for the planning of second-line chemotherapy protocols and the determination of complete and incomplete response at this stage of the disease.
